GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL (Nasdaq: GRAL) granted inducement equity awards of restricted stock units covering an aggregate of 19,500 shares to 20 newly hired non-executive employees under its Inducement Equity Incentive Plan dated March 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) granted inducement equity awards of restricted stock units covering an aggregate of 19,500 shares to 20 newly hired non-executive employees under its Inducement Equity Incentive Plan dated March 2, 2026.
The RSUs vest over approximately four years, with 25% vesting Feb. 28, 2027 and the remainder vesting on each annual anniversary thereafter, subject to continued employment.
Details
News Market Reaction – GRAL
On Mar 3, the first trading day after this news, GRAL closed 0.25% above the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- RSU shares granted
- 19,500 shares
- Inducement RSUs under equity incentive plan
- Employees receiving RSUs
- 20 employees
- Recently hired non-executive staff
- Initial vesting tranche
- 25%
- Portion of RSU award vesting on Feb. 28, 2027
- Vesting period
- 4 years
- RSUs vest over approximately four years
Historical Context
-
Announcement of management presentation at TD Cowen health care conference.
-
Q4 and 2025 results with strong growth but large net losses reported.
-
NHS-Galleri trial missed primary endpoint despite favorable secondary findings.
-
Scheduled date and webcast details for Q4 and full‑year 2025 results.
-
Submission of final PMA module for Galleri multi‑cancer detection test.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
RSUs financial
Nasdaq Listing Rule 5635(c)(4) regulatory
Inducement Equity Incentive Plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over an approximately four year period, with
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302701345.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.